Breaking News

Agenus, Gilead Milestone Triggers $7.5M Payment

FDA acceptance of IND filing for AGEN237 represents the second milestone in Gilead partnership achieved in 2019

Related CONTENT

08.08.19

Agenus Inc. announced that the FDA has accepted the company's IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. This milestone triggers a cash payment of $7.5 million. Agenus is eligible to receive additional milestone payments this year and beyond.

"This IND clearance underscores our continued commitment to delivering novel and best-in-class therapies to patients with cancer with the utmost urgency," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "AGEN2373 has unique binding properties and is designed to mitigate the toxicity observed with competitor molecules; we believe that this molecule has great potential for patients with cancer."

Related Searches

Suggested For You

Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

Gilead, Novo Nordisk Expand NASH Alliance

Gilead, Novo Nordisk Expand NASH Alliance

Gilead and Merck Ink HIV Agreement

Gilead and Merck Ink HIV Agreement

Gilead, Gritstone Enter Vax Platform Pact for HIV Cure

Gilead, Gritstone Enter Vax Platform Pact for HIV Cure

Gilead to Acquire MYR GmbH for €1.15B

Gilead to Acquire MYR GmbH for €1.15B

Gilead Bolsters Biologics Capabilities

Gilead Bolsters Biologics Capabilities

Financial Report: Gilead

Financial Report: Gilead

Gilead’s Remdesivir Wins FDA Approval to Treat COVID-19

Gilead’s Remdesivir Wins FDA Approval to Treat COVID-19

Assembly Biosciences Appoints President and CEO

Assembly Biosciences Appoints President and CEO

NIIMBL, FDA to Advance Innovation in Bio Manufacturing

NIIMBL, FDA to Advance Innovation in Bio Manufacturing

FDA Accepts RedHill Biopharma’s NDA for Talicia

FDA Accepts RedHill Biopharma’s NDA for Talicia

Syndax Pharma Gets IND Clearance for Leukemia Treatment

Syndax Pharma Gets IND Clearance for Leukemia Treatment

The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

Biopharma Cold Chain Solutions

Biopharma Cold Chain Solutions

Related Breaking News

Biologics, Proteins, Vaccines | Breaking News | Chemistry | Drug Development | Industry News | R&D

I-Mab Opens New R&D Lab in San Diego

Strengthens global R&D presence with a new integrated lab and operational site in the rapidly growing San Diego biotech hub.
10.22.21
Breaking News | Drug Development

Recro Pharma Awarded NIH Development, Mfg. Contract

Will support Chemistry, Manufacturing and Controls (CMC) development of NES-100, a novel nasal spray analgesic.
10.20.21
Breaking News | Drug Development | Promotions & Moves

Boyds Adds Two Product Development Experts to Its Team

Welcomes Diane Shattock Ph.D., as director of product development & Ian Hollingsworth M.Sc. as associate director of product development.
10.19.21
Breaking News | Drug Development

Landmark Bio Appoints Two New Leaders to Executive Team

Welcomes Gregg Nyberg as chief technology officer and Michael Covington as chief quality and regulatory officer.
10.19.21
Breaking News | Collaborations & Alliances | Drug Development

Agenus Earns $20M BMS Milestone in Antibody Alliance

Doses the first patient in Phase I trial of AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody in cancer.
10.13.21
Breaking News | Collaborations & Alliances | Drug Development

Geneseeq, Zai Lab Enter Strategic Cancer R&D Alliance

Aims to advance Zai Lab's cancer drugs through partnerships in clinical trial recruitment, central lab testing, companion diagnostics and marketing.
10.13.21
Breaking News | Collaborations & Alliances | Drug Development

Pacira BioSciences to Acquire Flexion

Expands its leadership position in non-opioid pain management with Flexion’s lead product ZILRETTA.
10.11.21
Breaking News | Drug Development | Industry News

Supernus to Acquire Adamas Pharmaceuticals for $400M

Transaction provides two marketed products for Parkinson’s disease, GOCOVRI and Osmolex ER.
10.11.21
Breaking News | cGMP Manufacture | Drug Development | Industry News

Pace Analytical Acquires Velesco

Adds specialized CDMO services in liquid, semi-solid, and oral solid dose product development.
10.11.21
Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Trials & Filings

AstraZeneca Submits EUA for LAAB Combo for COVID Prevention

Results from the PROVENT pre-exposure prophylaxis trial showed AZD7442 reduced the risk of developing symptomatic COVID-19 by 77%.
10.07.21
Breaking News | Drug Development | Industry News

AstraZeneca Acquires Caelum Biosciences

AstraZeneca will advance and accelerate ongoing Phase III development of CAEL-101, a potential first-in-class medicine for AL amyloidosis.
10.06.21
Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development

Compugen Earns $6M AstraZeneca Milestone in Antibody Alliance

First patient dosed in Phase 1/2 study of AZD2936 in advanced or metastatic non-small cell lung cancer.
10.04.21
Breaking News | Drug Development | Industry News

Merck, Ridgeback’s Molnupiravir Could Be First Oral Antiviral Pill for COVID

Reduced risk of hospitalization or death by 50 percent in patients with mild-to-moderate COVID-19, based on positive interim analysis of Phase 3 study.
10.01.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings

Roche’s Ronapreve Reduces Viral Load in COVID-19 Patients

Phase II/III trial met primary endpoint, showing Ronapreve significantly reduced viral load in patients hospitalized with COVID-19.
09.30.21
Breaking News | Drug Development | Industry News

RegeneRx Licensee Acquired by Korean Biopharma Group

GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharma and financial subsidiaries.
09.28.21